Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Exicure (XCUR) stocks in Canada

Learn how to easily invest in Exicure stocks.

Exicure is a biotechnology business based in the US. Exicure stocks (XCUR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.53 – a decrease of 7.33% over the previous week. Exicure employs 77 staff and has a market cap (total outstanding stock value) of $19.3 million.

How to buy shares in Exicure

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – XCUR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Exicure stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Exicure's stock price?

Since the stock market crash in March caused by coronavirus, Exicure's stock price has had significant negative movement.

Its last market close was $0.177, which is 91.77% down on its pre-crash value of $2.15 and 440.85% down on the lowest point reached during the March crash when the stocks fell as low as $0.9573.

If you had bought $1,000 worth of Exicure stocks at the start of February 2020, those stocks would have been worth $444.44 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $72.84.

Exicure stock price (NASDAQ:XCUR)

Use our graph to track the performance of XCUR stocks over time.

Exicure shares at a glance

Information last updated 2022-01-17.
Latest market close$0.18
52-week range$0.16 - $2.83
50-day moving average $0.46
200-day moving average $1.23
Wall St. target price$3.20
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.72

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Exicure price performance over time

Historical closes compared with the close of $0.177 from 2022-01-14

1 week (2022-01-11) -9.69%
1 month (2021-12-15) -30.59%
3 months (2021-10-19) -85.00%
6 months (2021-07-19) -87.79%
1 year (2021-01-19) -92.24%
2 years (2020-01-17) -92.89%
3 years (2019-01-18) 2.97
5 years (2017-01-15) N/A

Exicure financials

Operating margin TTM 2501.42%
Gross profit TTM $-15,481,000
Return on assets TTM -40.68%
Return on equity TTM -144.06%
Profit margin 0%
Book value $0.16
Market capitalisation $19.3 million

TTM: trailing 12 months

Exicure share dividends

We're not expecting Exicure to pay a dividend over the next 12 months.

Exicure share price volatility

Over the last 12 months, Exicure's shares have ranged in value from as little as $0.156 up to $2.83. A popular way to gauge a stock's volatility is its "beta".

XCUR.US volatility(beta: 1.24)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exicure's is 1.2364. This would suggest that Exicure's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Exicure overview

Exicure, Inc. , a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA?based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome; and collaboration agreement with Ipsen S. A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome.

Stocks similar to Exicure

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site